Update on ‘Three blind mice and human with lung cancer’ – The Badger
|
Update on ‘Three blind mice and human with lung cancer’
The Badger Back at the start of term, the Badger brought to you the exciting news of a breakthrough in the research of CRISPR techniques from the Salk Institute California. This concerned the use of non-homologous end joining (NHEJ) to help medical researchers in … |
TheStreet.com |
Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals
TheStreet.com Incyte (INCY) is benefitting from the competition between Merck (MRK) and Bristol-Myers Squibb (BMY) for cancer immunotherapy supremacy. On Sunday, Bristol and Incyte announced plans to test a combination therapy consisting of the Big Pharma’s … Merck’s Keytruda cancer drug records sales surgeFinancial Times The cost of cancer: new drugs show success at a steep priceKFGO |
|
You are here
P&T Community “Sleeping Beauty and the RTS® approach are a powerful combination to improve the manufacturing process and instill control over CAR-modified T cells co-expressing cytokines such as membrane-bound IL-15. The collaboration with Intrexon and Merck … |
Slate Magazine |
What Exactly Is Synthetic Biology? It’s Complicated.
Slate Magazine Maybe! But in the short term, they’re doing it in the service of synthetic biology more generally. It’s a discipline that brings together the insights and methodologies of computer science; engineering; and, of course, biology. It encompasses genetic … |